![](/public/attachments/month_1804/201804110635086623.jpg)
Breast Cancer
Editors: | Zhimin Shao, Peter G. Cordeiro, Charles M. Balch |
Publisher: AME Publishing Company; 1st edition (2017)
ISBN-13: 978-9887784128
Hardcover: 295 pages
Language: English
Any book on breast cancer can become outdated in a very short period of time and the most up-to-date information therefore needs to compiled and rapidly disseminated in order for a work to be useful to the many diverse subspecialists in medicine and surgery who participate in the care of the breast cancer patient. This book is an amalgamation of chapters from experts around the world covering topics that range from the latest advances in the basic science of breast cancer, to every significant aspect of diagnosis and treatment of this disease. Within each of the sections are chapters that are broad and might cover general approaches and algorithms for therapy, while others might be highly focused on some of the most controversial and cutting-edge therapies.
Honorary Editors
Zhenzhou Shen | Professor of Department of Breast Surgery, Fudan University Shanghai Cancer Center, China |
Bernard Fisher | Distinguished Service Professor, University of Pittsburgh, USA |
Gabriel Hortobagyi | Professor of Department of Breast Medical Oncology, MD Anderson Cancer Center, USA |
Editors
Zhimin Shao | Department of Breast Surgery, Fudan University Shanghai Cancer Center, China |
Peter G. Cordeiro | Plastic and Reconstructive Service, Memorial Sloan- Kettering Cancer Center, 1275 York Ave. New York, N.Y. 10021, USA |
Charles M. Balch | Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA |
Associate Editors
Keda Yu | Department of Breast Surgery, Fudan University Shanghai Cancer Center, China |
Ning Liao | Department of Breast Cancer, Cancer Center, Guangdong General Hospital, Guangzhou, China |
V. Suzanne Klimberg | Courtney M. Townsend, Jr. MD. Distinguished Professor in Surgical Oncology, UTMB |
William J. Gradishar | Betsy Bramsen Professor of Breast Oncology, Interim Chief, Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, USA |
Table of Contents
Preface
Epidemiology of Breast Cancer
1 Epidemiology and prognosis of breast cancer in young women
9 Lack of patient-reported outcomes assessment in phase III breast cancer studies: a missed opportunity for informed decision making
Advances in Basic Research of Breast Cancer
13 Breast cancer in the young: role of the geneticist
22 An update on the genomic landscape of breast cancer: new opportunity for personalized therapy?
26 Towards the elucidation of the mechanisms underlying breast cancer mutations
29 Members of the BRCA1 complexes as new susceptibility genes for breast cancer
32 APOBEC3B spreads somatic mutations in breast cancer genome
35 From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cancer
46 MET deregulation in breast cancer
53 Circulating free DNA in the management of breast cancer
Imaging Examination of Breast Cancer
56 Breast imaging in the young: the role of magnetic resonance imaging in breast cancer screening, diagnosis and follow-up
Treatment of Breast Cancer
68 Challenges in managing breast cancer during pregnancy
75 Premature menopause in young breast cancer: effects on quality of life and treatment interventions
Surgical Treatment
83 Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experience
91 Oncoplastic techniques in breast surgery for special therapeutic problems
99 Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy
107 Anatomy relevant to conservative mastectomy
115 Breast reconstruction following conservative mastectomies: predictors of complications and outcomes
128 Surgical management of breast cancer in China: the Fudan University Shanghai Cancer Center experience
Endocrine Therapy
139 Paradigm of polyendocrine therapy in endocrine responsive breast cancer: the role of fulvestrant
144 Bisphosphonates in the adjuvant treatment of young women with breast cancer: the estrogen rich is a poor candidate!
155 Hormonal therapies in young breast cancer patients: when, what and for how long?
168 A balancing act for breast cancer? Everolimus for hormone receptor positive patients
Chemotherapy
172 Treatment of breast cancer in young women: do we need more aggressive therapies?
181 Neoadjuvant bevacizumab and chemotherapy in breast cancer
Radiotherapy
183 Impact of preoperative magnetic resonance imaging in breast cancer patients candidates for an intraoperative partial breast irradiation
190 First year experience with IORT for breast cancer at the Geneva University Hospitals
199 CyberKnife stereotactic body radiotherapy and CyberKnife accelerated partial breast irradiation for the treatment of early breast cancer
207 Brest experience in intraoperative radiotherapy for breast cancer
212 Intraoperative radiotherapy with electrons (ELIOT) for early breast cancer: the European Institute of Oncology experience
218 Comparison of the proliferative and clonogenic growth capacity of wound uid from breast cancer patients treated with and without intraoperative radiotherapy
223 The use of postoperative radiation after nipple sparing mastectomy
229 Optimal management of sentinel lymph node positive biopsy patients in early breast cancer
Targeted Therapy
233 Should trastuzumab be administered concomitantly with anthracycline in women with early, HER2-positive breast cancer?
239 Pertuzumab in metastatic breast cancer: unanswered questions
242 Pertuzumab: a step forward in treating HER2-positive breast cancer
244 Bevacizumab: Where do we go from here in breast cancer?
246 Lapatinib as a therapeutic option in brain metastases from HER2+ breast cancer
248 The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post- menopausal women with ER+/Her2− invasive breast cancer
Nanoparticle Therapy
255 Theranostic nanoparticles for enzyme-activatable uorescence imaging and photodynamic/chemo dual therapy of triple-negative breast cancer
Prognosis of Breast Cancer
264 Fertility counseling of young breast cancer patients
280 Sexuality and breast cancer: prime time for young patients
287 Breast cancer and sleep disturbance: more than simply a quality of life concern
289 Brain metastases in HER2 positive breast cancer: the next hurdle
293 Brain metastases in HER2-positive breast cancer: challenges and opportunities